HER2 + BREAST CANCER
Clinical trials for HER2 + BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2 + BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2 + BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Radioactive bullet targets Hard-to-Treat breast cancer
Disease control Recruiting nowThis early-stage trial is testing a new drug called [177Lu]Lu-ABY-271, which delivers a small dose of radiation directly to HER2-positive breast cancer cells. The study will enroll 21 people with advanced or metastatic HER2-positive breast cancer to see if the drug is safe, toler…
Matched conditions: HER2 + BREAST CANCER
Phase: PHASE1 • Sponsor: Affibody • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
Zapping a single tumor may keep breast cancer in check
Disease control Recruiting nowThis study tests whether giving a precise, high-dose radiation treatment called SBRT to one growing tumor can help people with metastatic breast cancer keep their disease under control. Participants continue their usual drug therapy while receiving SBRT to a single site where can…
Matched conditions: HER2 + BREAST CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
New pill takes aim at hard-to-treat HER2 cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called IAM1363 in adults with advanced cancers that have HER2 alterations, including breast, lung, and stomach cancers that have spread to the brain. The study aims to find the safest dose and see if the drug can shrink tumors. About 383 pa…
Matched conditions: HER2 + BREAST CANCER
Phase: PHASE1 • Sponsor: Iambic Therapeutics, Inc • Aim: Disease control
Last updated Jun 22, 2026 12:06 UTC
-
Simple blood test could predict breast cancer return
Knowledge-focused Recruiting nowThis study is looking at whether a simple blood test can find tiny bits of cancer DNA left in the body after breast cancer treatment. These leftover cells, called minimal residual disease (MRD), can sometimes cause the cancer to come back. The study will follow 900 breast cancer …
Matched conditions: HER2 + BREAST CANCER
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Jun 22, 2026 11:58 UTC